The Patient Labeling Program at Bristol-Myers Squibb

Abstract

Among the goals of the Department of Health and Human Services and the Food and Drug Administration (FDA) is to improve written communication to patients about their prescription medicines. Bristol-Myers Squibb Company recognizes the need for patients to receive high-quality information regarding their therapeutic options. The company has initiated a program to prepare patient-oriented labeling for certain prescription products for which such material is appropriate, using the FDA’s proposed Medication Guide as a basis for content and format.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Federal Register. 1968;33:8812 (21 CFR 201.305).

  2. 2.

    Federal Register. 1970;35:9O01 (21 CFR 310.501).

  3. 3.

    Federal Register. 1977;42:37636 (21 CFR 310.515).

  4. 4.

    Federal Register. 1978;43:47198 (21 CFR 310.516).

  5. 5.

    Steering Committee for the Collaborative Development of a Long-Range Action Plan for the Provision of Useful Prescription Medicine Information. Action Plan for the Provision of Useful Prescription Medicine Information. December 1996: 11.

  6. 6.

    Federal Register. 1979;44:40016.

  7. 7.

    Federal Register. 1980;45:60754.

  8. 8.

    Federal Register. 1981;46:13193.

  9. 9.

    Federal Register. 1981;46:23739.

  10. 10.

    Federal Register. 1982;47:39147.

  11. 11.

    Federal Register. 1995;60:44182.

  12. 12.

    HR 104-180.

  13. 13.

    Federal Register. 1995;60:44199.

  14. 14.

    Steering Committee for the Collaborative Development of a Long-Range Action Plan for the Provision of Useful Prescription Medicine Information. Action Plan for the Provision of Useful Prescription Medicine Information. December 1996: 3.

  15. 15.

    Federal Register. 1998;63:66378-66400.

  16. 16.

    Jones S, et al. Patient information leaflets for HIV positive patients. Pharmaceut J. Sep 8, 1990;245: 308–309.

    Google Scholar 

  17. 17.

    Fleckenstein L, et al. Oral contraceptive patient information-a questionnaire study of attitudes, knowledge, and preferred information sources. JAMA. 1976; 235(13):1331–1336.

    CAS  Article  Google Scholar 

  18. 18.

    Smith D. Compliance packaging: a patient education tool. Am Pharmacy. Feb 2, 1989;NS29(2):126–137.

    Google Scholar 

  19. 19.

    Kuperberg JR, et al. All in one: the user-friendly rx product. Pharmaceut Exec. April 1990:74–78.

    Google Scholar 

  20. 20.

    Gibbs S, et al. The benefits of prescription information leaflets (1). Br J Clin Pharmacol. 1989;27:723–739.

    CAS  Article  Google Scholar 

  21. 21.

    George CF, et al. Prescription information leaflets: a pilot study in general practice. Brit Med J 1983; 287:1193–1196.

    CAS  Article  Google Scholar 

  22. 22.

    Glazier R, et al. Written patient information about triple-market screening: a randomized, controlled trial. Obstet Gynecol. November 1997;90(5):769–774.

    CAS  Article  Google Scholar 

  23. 23.

    National Institute of Health. Minimizing Medical Product Errors, A Systems Approach, Bethesda, MD; Jan. 8, 1998.

    Google Scholar 

  24. 24.

    Sless D, Wiseman R. Writing about Medicines for People-Usability Guidelines for Consumer Medicine Information. 2nd ed. Communication Research Institute of Australia. Dickson, Australia. Ch 6, 73-96, Appendices 3, 4, 5, 121-157.

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dr. Cathleen A. O’Connell.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

O’Connell, C.A., Skinner, R. The Patient Labeling Program at Bristol-Myers Squibb. Ther Innov Regul Sci 33, 649–654 (1999). https://doi.org/10.1177/009286159903300301

Download citation

Key Words

  • Food and Drug Administration
  • Patient labeling
  • Consumer labeling
  • Patient package insert
  • Medication Guide
  • Healthy People 2000
  • Action Plan for the Provision of Useful Prescription Medicine Information